Log in

NASDAQ:APTO - Aptose Biosciences Stock Price, Forecast & News

$5.99
-0.17 (-2.76 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$5.66
Now: $5.99
$6.14
50-Day Range
$4.74
MA: $7.12
$9.00
52-Week Range
$1.81
Now: $5.99
$9.25
Volume713,154 shs
Average Volume1.04 million shs
Market Capitalization$456.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More
Aptose Biosciences logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTO
CUSIPN/A
Phone858-926-2730

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.23 per share

Profitability

Net Income$-26,280,000.00

Miscellaneous

EmployeesN/A
Market Cap$456.86 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.


Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

How has Aptose Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APTO shares have increased by 2.6% and is now trading at $5.99. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aptose Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptose Biosciences.

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Aptose Biosciences.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) issued its earnings results on Tuesday, March, 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01. View Aptose Biosciences' earnings history.

What price target have analysts set for APTO?

5 analysts have issued 1-year price objectives for Aptose Biosciences' shares. Their forecasts range from $9.00 to $16.00. On average, they expect Aptose Biosciences' stock price to reach $12.00 in the next year. This suggests a possible upside of 100.3% from the stock's current price. View analysts' price targets for Aptose Biosciences.

Has Aptose Biosciences been receiving favorable news coverage?

Headlines about APTO stock have trended very negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aptose Biosciences earned a coverage optimism score of -3.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAptose Biosciences.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a drop in short interest in March. As of March 13th, there was short interest totaling 367,400 shares, a drop of 5.7% from the February 27th total of 389,800 shares. Based on an average daily volume of 924,000 shares, the short-interest ratio is currently 0.4 days. Approximately 0.5% of the company's stock are sold short. View Aptose Biosciences' Current Options Chain.

Who are some of Aptose Biosciences' key competitors?

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Micron Technology (MU), Viking Therapeutics (VKTX) and AT&T (T).

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the following people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (1.33%), Driehaus Capital Management LLC (1.28%), Point72 Asset Management L.P. (1.01%), P.A.W. Capital Corp (0.89%), Schonfeld Strategic Advisors LLC (0.84%) and Voss Capital LLC (0.40%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View institutional ownership trends for Aptose Biosciences.

Which major investors are selling Aptose Biosciences stock?

APTO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Man Group plc, and Sanders Morris Harris LLC. View insider buying and selling activity for Aptose Biosciences.

Which major investors are buying Aptose Biosciences stock?

APTO stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Driehaus Capital Management LLC, Schonfeld Strategic Advisors LLC, Voss Capital LLC, P.A.W. Capital Corp, Monashee Investment Management LLC, Renaissance Technologies LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice. View insider buying and selling activity for Aptose Biosciences.

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $5.99.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of $456.86 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.  View additional information about Aptose Biosciences.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is http://www.aptose.com/.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 12770 HIGH BLUFF DRIVE SUITE 120, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected]


MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  326 (Thanks for Voting!)
Underperform Votes:  273 (Thanks for Voting!)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel